Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects, aged 18 to 75 years old, inclusive.~* Subjects with acromegaly defined as documented evidence of growth hormone-secreting pituitary tumor that is abnormally responsive to glucose, or documented elevated insulin-like growth factor-1 (IGF-1), who are currently receiving a stable dose of a somatostatin analog for at least the previous 3 months.~* A serum IGF-1 level \< 1.3 x the upper limit of normal (ULN) and a serum growth hormone (GH) level \< 2.5 ng/mL.~* Subjects able and willing to comply with the requirements of the protocol.~* Subjects able to swallow capsules.~* Subjects able to understand and sign written informed consent to participate in the study.~Exclusion Criteria:~* Receiving regular injections of a somatostatin analog less frequently than once a month, ie, longer than every 4 weeks.~* Symptomatic cholelithiasis.~* Received pituitary radiotherapy within ten years prior to screening.~* Undergone pituitary surgery within the prior 6 months.~* Any condition that may jeopardize study participation.~* Clinically significant gastrointestinal (GI), renal, or hepatic disease as determined by the Investigator.~* Conditions (eg, bariatric surgery) significantly affecting gastric acidity or emptying.~* Current use (within 1 month) of proton pump inhibitors (PPIs) and current chronic use of H2-antagonists.~* Female patients who are pregnant or lactating.~* Current or recent (\< 3 months) therapy with pegvisomant.~* Current or recent (\< 2 months) therapy with cabergoline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Octreotide capsules (Type: EXPERIMENTAL): Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.

Based on this trial design, predict the completion outcome and termination type (if applicable).